Paclitaxel Micelles Plus Immunotherapy for Advanced HER2-Positive Breast Cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This study tests a new chemotherapy combination (paclitaxel polymeric micelles with HP and adebelimab) versus standard chemotherapy for advanced breast cancer that tests positive for HER2. The goal is to see if this approach helps patients live longer and controls cancer better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with advanced or metastatic breast cancer that is HER2-positive (confirmed by pathology)
- Little to no prior chemotherapy or HER2-targeted therapy for advanced disease (or only prior hormone therapy)
- Tumor shows PD-L1 positivity (an immune marker) on testing
- Good overall health (ECOG score 0–1) with working heart, lung, liver, and kidney function
- Blood cell counts and liver/kidney labs within acceptable ranges
- At least one measurable tumor visible on imaging that can be tracked
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of low-dose oral paclitaxel (a chemotherapy pill taken regularly) plus immunotherapy to treat advanced breast cancer that doesn't have high levels of HER2 protein. The goal is to slow or shrink tumors while managing side effects better than traditional high-dose chemotherapy.
This trial tests a new combination of drugs for people with HER2-positive early breast cancer whose tumors did not respond well to the first round of standard targeted therapy plus chemo. The goal is to see if switching to trastuzumab-rezetecan plus pertuzumab or a different chemo combo (nab-paclitaxel, carboplatin, trastuzumab, and pyrotinib) can shrink the tumor before surgery.
This trial is testing a new medicine as the first treatment for HER2-positive breast cancer that has spread or cannot be removed. It's for women who have not had chemotherapy for advanced disease.
This trial tests a combination of two drugs, trastuzumab deruxtecan (SHR-A1811) and pertuzumab, given before surgery to shrink HER2-positive breast cancer. It is for women with stage II or III breast cancer who have not yet had treatment and are in good overall health.
This trial compares two different drug combinations given before surgery to shrink HER2-positive breast cancer tumors. The goal is to see which combination works better and has fewer side effects.
This Phase 2 study tests a personalized immune-therapy vaccine made from your immune cells, given with weekly paclitaxel and HER2-targeted antibodies (trastuzumab and pertuzumab). It aims to improve treatment outcomes for people with HER2-positive breast cancer before standard local treatment (like surgery and radiation).
Hear when a new Advanced HER2-positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.